2024-517536-22-00招募中2 期
A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced Cancers
Checkpoint Therapeutics Inc.9 个研究点 分布在 2 个国家目标入组 63 人开始时间: 2024年9月24日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 63
- 试验地点
- 9
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Pivotal S.L.U Medical Department
Scientific
Checkpoint Therapeutics Inc.
研究点 (9)
Loading locations...
相似试验
尚未招募
1 期
Phase I, Open-label, Single-center, Dose Escalation Study to Assess Safety and Tolerability of anti-CD19 CAR-T Cells in Patients with B-cell non-Hodgkin Lymphomas (CARMEN).2024-519318-30-00Wroclaw Medical University18
招募中
1 期
Phase 1, open-label, multicenter, dose escalation study of SRG-1505 as monotherapy in subjects with mature b-cell malignancies2023-505204-34-00Schrodinger Inc.22
招募中
2 期
Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3-DXd monotherapy and combinations in Patients with inoperable advanced breast cancer (ABC) after progression on T-DXd- (ICARUS BREAST 2)2023-505925-15-00Institut Gustave Roussy150
招募中
1 期
TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant TumorsNCT07266298Neowise Biotechnology24
招募中
1 期
A Study of PLB-002 in Advanced Solid TumorsNCT07304128Primelink BioTherapeitics(ShenZhen) Limited100